enGene Therapeutics Inc. Common Stock (ENGN)
Stock · NASDAQ · Health Care
$1.67as of 10/16/2026
Price chart
Active signals
ENGN Signal Track Record
How signals performed across all stocks →What ENGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +0.5% | 56% | September 25, 2026 |
| Bollinger Band Breakout | 26 | +0.4% | 54% | September 22, 2026 |
| Bollinger Band Breakdown | 13 | -6.0% | 38% | October 7, 2026 |
| Any 20-session window (baseline) | +0.5% | 58% |
Computed by MarketWall from daily closing prices since November 15, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was former…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 81
- Website
- engene.com
Fundamentals
- 1-day range
- $1.59$1.73
- Market cap
- $120.58M
- P/E (trailing)
- —
- P/E (forward)
- -1.18
- EPS (trailing)
- $-2.08
- Dividend yield
- —
- Beta
- -0.31
- Avg. volume
- 722.7K
Forecasts
7 analyst ratings
enGene Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- BDTXBlack Diamond Therapeutics Inc. Common Stock$1.72▼ 1.15%Market cap $110.02MP/E —$1.6$4.94
- PTHSPelthos Therapeutics Inc. Common Stock$20.15▼ 0.54%Market cap $102.36MP/E —$18.19$37.5
- ENTXEntera Bio Ltd. Ordinary Shares$2.68▼ 3.25%Market cap $139.00MP/E —$0.91$4.2
- CGTXCognition Therapeutics Inc. Common Stock$0.73▼ 0.41%Market cap $101.13MP/E —$0.5501$2
- KLRSKalaris Therapeutics Inc. Common Stock$2▼ 8.68%Market cap $99.69MP/E —$2.35$11.88
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.1▼ 4.35%Market cap $156.77MP/E —$1.23$3.23
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $1.72 | ▼ 1.15% | $1.6$4.94 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $20.15 | ▼ 0.54% | $18.19$37.5 |
| ENTX Entera Bio Ltd. Ordinary Shares | $139.00M | — | $2.68 | ▼ 3.25% | $0.91$4.2 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $0.73 | ▼ 0.41% | $0.5501$2 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $2 | ▼ 8.68% | $2.35$11.88 |
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.1 | ▼ 4.35% | $1.23$3.23 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Grossman William · September 22, 2026 · Buy5.1K @ $1.97
- BRUNK GERALD A · June 16, 2026 · Grant31.0K
- Heffernan Michael Thomas · June 16, 2026 · Grant31.0K
- Astley-Sparke Philip · June 16, 2026 · Grant31.0K
- Glickman Richard M · June 16, 2026 · Grant31.0K
- Paul J. Hastings · June 16, 2026 · Grant31.0K
- Lota S. Zoth · June 16, 2026 · Grant31.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 344.0K
- Total value held
- $2.34M
- Institutional holders
- 2
- Unknown343.9K
- Unknown28
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
enGene to Host KOL Webinar on Oct 15, 2026
enGene announced it will host a KOL webinar on Oct 15, 2026. The event will bring together key opinion leaders to discuss the company's therapeutic pipeline and clinical progress. The webinar could provide new insights for stakeholders and may influence market perception. The company remains in a lower part of its 52‑week range.
enGene to Host KOL Webinar on Oct 15, 2026. enGene announced it will host a KOL webinar on Oct 15, 2026. The event will bring together key opinion leaders to discuss the company's therapeutic pipeline and clinical progress. The webinar could provide new insights for stakeholders and may influence market perception. The company remains in a lower part of its 52‑week range.